Trial-Results center  
Clinical trial results database in cardiology Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - antioxydants - secondary prevention


Related trials

WACS beta-caroten, 2007 - beta carotene vs placebo

WACS vitamin E, 2007 - vitamin E vs placebo

WACS vitamin C, 2007 - vitamin C vs placebo

HOPE renal insufficiency subgroup, 2004 - vitamin E vs placebo

WAVE (Waters), 2002 - combination vs placebo

HPS antioxidant, 2002 - combination vs placebo

HATS, 2001 - combination vs placebo

SPACE, 2000 - vitamin E vs placebo

HOPE, 2000 - vitamin E vs placebo

GISSI, 1999 - vitamin E vs control

ATBC 2nd prev subgroup (vitamin E), 1998 - vitamin E vs placebo

ATBC 2nd prev subgroup (b carotene), 1998 - beta carotene vs placebo

MVP, 1997 - combination vs placebo

CHAOS, 1996 - vitamin E vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of antioxydants
  • All clinical trials of beta carotene
  •  

    ATBC 2nd prev subgroup (b carotene) study, 1998

    download pdf: beta carotene | antioxydants for cardiovascular prevention

    Treatments

    Studied treatment synthetic beta carotene 20 mg daily
    Control treatment placebo
    Remarks factorial design of alpha tocopherol (vitamin E) 50 mg/day and beta carotene 20 mg/day

    Patients

    Patients patients enroled in the ATBC trial and who had angina pectoris in the Rose chest pain questionnaire at baseline
    Inclusion criteria male smokers (five or more cigarettes daily); aged 50–69 years; angina pectoris in the Rose chest pain questionnaire
    Exclusion criteria malignancy, severe angina pectoris (angina when walking at normal pace on the level), renal insufficiency, cirrhosis of the liver, other medical problems limiting participation, and use of anticoagulants or vitamin E, vitamin A, or â carotene supplements
    Baseline characteristics
    Women (%) 0% 
    age (yr) 58.8 y 
    Body mass index 26.5 

    Method and design

    Randomized effectives 876 / 919 (studied vs. control)
    Design Factorial plan
    Blinding double-blind
    Follow-up duration 3.79 y
    Number of centre multicenter
    Geographic area Finland
    Hypothesis Superiority
    Primary endpoint not defined
    Remarks

    Remarks / Comments



    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Coronary event

    153 / 876
    161 / 879
    0,95 [0,78;1,17]

    Coronary death

    85 / 876
    83 / 879
    1,03 [0,77;1,37]

    Non fatal MI

    68 / 876
    78 / 879
    0,87 [0,64;1,19]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Coronary death 85 / 876 (9,7%) 83 / 879 (9,4%) 1,03 [0,77;1,37] 13285
    Coronary event 153 / 876 (17,5%) 161 / 879 (18,3%) 0,95 [0,78;1,17] 13285
    Non fatal MI 68 / 876 (7,8%) 78 / 879 (8,9%) 0,87 [0,64;1,19] 13285
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:
  • 13285: Rapola JM, Virtamo J, Ripatti S, Haukka JK, Huttunen JK, Albanes D, Taylor PR, Heinonen OPEffects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris.Heart 1998;79:454-8

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Coronary death 9,70% 9,44% 2,6‰
    Coronary event 17,47% 18,32% -8,5‰
    Non fatal MI 7,76% 8,87% -11,1‰

    Meta-analysis of all similar trials:

    antioxydants in cardiovascular prevention for secondary prevention



    Reference(s)

    Trials register # NA
    • Rapola JM, Virtamo J, Ripatti S, Haukka JK, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris.. Heart 1998;79:454-8
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend